Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Endurance RP ( (HK:0575) ) has provided an update.
Endurance RP reported its audited final results for 2025, highlighting continued progress as a commercial-stage biopharmaceutical company and its strategy to generate royalties and milestone payments by out-licensing its drug portfolio. The company emphasized disciplined capital management and ongoing investment in innovation to support long-term shareholder value.
Operationally, management underscored the importance of China and the wider Greater China region, where it is working with partner Wanbang Biopharmaceutical and regulators to secure approval for Senstend by June 2026 after a delay from the original late-2025 expectation. The company also reiterated its ambition to lead in the longevity space through its AI-driven ageing clocks, positioning Deep Longevity as a core driver of future health and wellness offerings.
The most recent analyst rating on (HK:0575) stock is a Hold with a HK$0.93 price target. To see the full list of analyst forecasts on Endurance RP stock, see the HK:0575 Stock Forecast page.
More about Endurance RP
Endurance RP, formerly known as Regent Pacific, is a Hong Kong-based biopharmaceutical and investment company focused on building a royalty-focused pharma business and advancing longevity technologies. Its primary assets include Fortacin, marketed as Senstend in China for premature ejaculation, and Deep Longevity, an AI-powered digital health unit offering ageing clocks and preventative health solutions via a B2B2C SaaS platform, with strategic focus on Greater China, the U.S., the U.K., and Europe.
YTD Price Performance: -21.50%
Average Trading Volume: 69,952
Technical Sentiment Signal: Sell
Current Market Cap: HK$245.1M
For detailed information about 0575 stock, go to TipRanks’ Stock Analysis page.